Determining How a Dynamic Microbiome Contributes to Cystic Fibrosis Lung Disease
Determining How a Dynamic Microbiome Contributes to Cystic Fibrosis Lung Disease
批准号:
10448246
负责人:
Robert Andrew Quinn
金额:
$60.83万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-17 至 2024-06-30
关键词:
AcuteAffectAnaerobic BacteriaAntibiotic TherapyAntibioticsAutomobile DrivingBacteriaBehaviorBioinformaticsBiologicalBronchiolesCarbonCessation of lifeCharacteristicsChemicalsChemistryChronicChronic PhaseChronic lung diseaseClinicalClinical ResearchCommunitiesComplexComplicationCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDataData AnalysesDevelopmentDiseaseDropsEcosystemEnergy-Generating ResourcesEnvironmentEnzymesEpithelialEpithelial CellsEventFermentationGrowthHeightImmune responseImmune systemIndividualIntravenousIon TransportLaboratoriesLeadLiteratureLungLung diseasesLung infectionsMeasuresMetabolicMetabolismMethodsMicrobial PhysiologyMicrobial TaxonomyModelingMucous body substanceMultiomic DataMutationOralOutcomeOxygenPathologyPatientsPhysiologicalPhysiologyPlayPrediction of Response to TherapyProductionPseudomonas aeruginosaPulmonary Cystic FibrosisQuality of lifeRecoveryRegulator GenesResearch PersonnelResistanceRespiratory Tract InfectionsRoleSamplingSeveritiesShapesSourceSputumStructureSymptomsSystemTestingTreatment outcomeValidationVirulenceantimicrobialbacterial communitybronchial epitheliumclinically relevantcystic fibrosis mucuscystic fibrosis patientsdysbiosiseffective therapyefficacious treatmentexperienceimprovedin vivolaboratory experimentlung microbiomemathematical modelmembermetabolomemetabolomicsmicrobialmicrobial communitymicrobial hostmicrobiomemicrobiome sequencingmicroorganism interactionmultiple omicsneutrophilnovelpathogenpatient populationpressureprogramspulmonary functionpulmonary function declineresponsetargeted treatmenttherapy outcometreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Pulmonary exacerbations are a pervasive complication of chronic lung infection. These events
cause an increase in symptom severity, loss of lung function and require aggressive antibiotic
treatment. While the bacterial communities in chronically infected lungs are believed to be involved in
exacerbations, there is a poor understanding of how or why this happens. Our preliminary evidence
indicates there is a dysbiotic shift that occurs during CF pulmonary exacerbation (CFPE) to
the dominance of anaerobic bacteria. This proposal attempts to further test this hypothesis
and reveal mechanisms driving microbiome dynamics during CFPEs.
Cystic Fibrosis (CF) is a chronic lung disease that is caused by mutations in the Cystic
Fibrosis Transmembrane Conductance Regulator gene (CFTR). These mutations cause a buildup of
mucus in the lungs due to disrupted epithelial ion transport. This abundant mucus plugs the
conducting airways, and due to the presence of bacteria, creates anaerobic environments. Although
poorly characterized as CF pathogens, anaerobic bacteria are ubiquitous in CF lungs and believed to
play a role in the disease. Our preliminary data indicates that there is a dysbiotic shift from pathogen
dominance to anaerobes during CFPE development. Antibiotic treatment kills these anaerobes
allowing the classic pathogens of CF, such as Pseudomonas aeruginosa, to again take over the lung.
We are able to reproduce these dynamics in the laboratory allowing us to directly study their cause.
This project will investigate CFPE microbial dynamics using clinical samples from patients, laboratory
experiments and mathematical modeling.
We will collect longitudinal sputum samples from patients through exacerbation events and
analyze the microbial taxonomic composition, host response and metabolite production. In addition,
we will use a novel culture model that mimics the CF lung environment (called the WinCF model) to
test our hypothesis in vivo. WinCF can be manipulated to test the effect of chemical and biological
perturbations on the CF microbial community structure, metabolism and virulence. We will test
multiple variables on the structure and function of the CF microbial community in an attempt to
understand the drivers of dynamics observed during exacerbations. Results from these studies will be
mathematically modeled using a recently developed model of the CF microbiome growing in mucus-
plugged bronchioles. The entire project will utilize cutting edge multi-omics methods including
microbiome sequencing, metabolomics and novel bioinformatics data analysis platforms. Our
scientific rationale is that a better understanding of what causes microbial changes during CFPEs will
lead to more efficacious and targeted therapy against pathogens.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.jcf.2021.11.003
发表时间:
2022-11
期刊:
JOURNAL OF CYSTIC FIBROSIS
影响因子:
5.2
作者:
[Sosinski, Lo M., Martin, Christian H., Neugebauer, Kerri A., Ghuneim, Lydia-Ann J., Guzior, Douglas, V, Castillo-Bahena, Alicia, Mielke, Jenna, Thomas, Ryan, McClelland, Marc, Conrad, Doug, Quinn, Robert A.]
通讯作者:
Quinn, Robert A.
Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
Elexacaftor-Tezacaftor-Ivacaftor 治疗后囊性纤维化肺的纵向微生物和分子动力学。
DOI:
10.21203/rs.3.rs-3356170/v1
发表时间:
2023
期刊:
Research square
影响因子:
--
作者:
[Martin,Christian, Guzior,DouglasV, Gonzalez,CelyT, Okros,Maxwell, Mielke,Jenna, Padillo,Lienwil, Querido,Gabriel, Gil,Marissa, Thomas,Ryan, McClelland,Marc, Conrad,Doug, Widder,Stefanie, Quinn,RobertA]
通讯作者:
Quinn,RobertA
DOI:
10.1038/s41396-022-01252-5
发表时间:
2022-09
期刊:
ISME JOURNAL
影响因子:
11
作者:
[Ghuneim, Lydia-Ann J., Raghuvanshi, Ruma, Neugebauer, Kerri A., Guzior, Douglas V., Christian, Martin H., Schena, Bella, Feiner, Jeremiah M., Castillo-Bahena, Alicia, Mielke, Jenna, McClelland, Marc, Conrad, Douglas, Klapper, Isaac, Zhang, Tianyu, Quinn, Robert A.]
通讯作者:
Quinn, Robert A.
Determining How a Dynamic Microbiome Contributes to Cystic Fibrosis Lung Disease
-
批准号:9979750
-
项目类别:
-
资助金额:$75.3万
-
财政年份:2019
-
负责人:Robert Andrew Quinn
-
依托单位:
Determining How a Dynamic Microbiome Contributes to Cystic Fibrosis Lung Disease
-
批准号:10207411
-
项目类别:
-
资助金额:$73.05万
-
财政年份:2019
-
负责人:Robert Andrew Quinn
-
依托单位:
海外基金